Patients with chronic kidney disease (CKD) often encounter cardiovascular complications, most commonly coronary heart disease. Although coronary artery bypass grafting is an effective treatment for ...

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

The US Food and Drug Administration (FDA) has approved scPharmaceuticals’ supplemental new drug application (sNDA) for ...

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Acute kidney injury (AKI) is estimated to occur in up to 50% of patients with liver cirrhosis and is associated with increased morbidity and a high risk of short-term and long-term mortality.1 ...

Novo Nordisk's rare disease unit awaits Phase 3 data for etavopivat in sickle cell disease, aiming for 50% VOC reduction ...

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...